Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Here's What Key Metrics Tell Us About Axsome (AXSM) Q1 Earnings
10:30am, Monday, 04'th May 2026
Although the revenue and EPS for Axsome (AXSM) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street e
Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue Estimates
09:15am, Monday, 04'th May 2026
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.8 per share a year ago.
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
07:00am, Monday, 04'th May 2026
Total 1Q 2026 net product revenue of $191.2 million, representing 57% year-over-year growth AUVELITY ® 1Q 2026 net product sales of $153.2 million, representing 59% year-over-year growth SUNOSI ® 1Q
Why Axsome Therapeutics Stock Jumped Over 20% in April
10:47am, Saturday, 02'nd May 2026
Axsome shares reached an all-time high last month, and there might be more to come.
Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease Transcript
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
07:15am, Friday, 01'st May 2026
NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host
US FDA approves Axsome's drug for Alzheimer's-related agitation
02:10pm, Thursday, 30'th Apr 2026
The U.S. Food and Drug Administration has approved Axsome Therapeutics' drug to treat agitation in patients with Alzheimer's disease, the company said on Friday.
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer's disease
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
09:35am, Thursday, 30'th Apr 2026
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $1.07 per share a year ago.
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
11:01am, Monday, 27'th Apr 2026
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Knocks At $2 Billion Opportunity, Nears Buy Point
02:31pm, Thursday, 16'th Apr 2026
Axsome Therapeutics is nearing a buy point of 191.50.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of “Moderate Buy” by Brokerages
03:18am, Friday, 10'th Apr 2026
Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twenty research firms that are covering the firm, MarketBeat.com reports. T
Is This Healthcare Stock a Millionaire Maker?
05:48pm, Wednesday, 08'th Apr 2026
Axsome Therapeutics has performed well since its IPO. The company's current lineup and pipeline could drive growth for a while.
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
07:00am, Wednesday, 08'th Apr 2026
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a
SG Americas Securities LLC Acquires 5,584 Shares of Axsome Therapeutics, Inc. $AXSM
05:28am, Saturday, 04'th Apr 2026
SG Americas Securities LLC lifted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) by 46.2% during the fourth quarter, according to the company in its most recent Form 13F filing wit
